Servicewomen and Veterans Menopause Research Act
- Sponsor
- Rep. Houlahan, Chrissy [D-PA-6]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Apr 8, 2025
Bottom line
The bill mandates a joint DoD and VA effort to evaluate and strategically plan for improved research, training, and treatment concerning menopause and mid-life health for servicewomen and veterans.
What it actually does
This bill directs the Secretary of Defense and the Secretary of Veterans Affairs to conduct a comprehensive evaluation of existing and ongoing research, as well as knowledge gaps, related to menopause, perimenopause, and mid-life women's health among servicewomen and veterans. It mandates a report to Congress within 180 days, which must include findings, recommendations for professional training, and a strategic plan to address identified research needs and gaps. The bill explicitly requires consideration of service-related factors like combat roles and exposure to toxic substances.
Proponents argue
Supporters argue that this bill addresses a critical and often overlooked area of women's health for a significant and growing population within the military and veteran communities. They contend it is essential to understand the unique impacts of military service, including combat exposure and environmental toxins, on menopause and perimenopause, ensuring that servicewomen and veterans receive appropriate, evidence-based care and support.
Opponents contend
No direct organized opposition is typically raised against legislation focused on evaluating and planning for improved health research, particularly for servicemembers and veterans. Potential concerns, if any, might revolve around the administrative burden on the Departments or the allocation of resources, rather than the core intent of improving women's health outcomes.
The bill is short and clearly written, making it highly accessible for a reader to understand its provisions and purpose quickly.
Section 2(a)
Mandate for Comprehensive Research Evaluation
This provision directs the Secretary of Defense, in coordination with the Secretary of Veterans Affairs, to conduct a thorough evaluation. This includes reviewing completed and ongoing research on menopause, perimenopause, and mid-life women's health among servicewomen and veterans. It specifically requires identifying gaps in knowledge regarding treatments (hormone and non-hormone), treatment safety and effectiveness, the impact of military service (including combat roles and exposures like burn pits, toxic chemicals, PFAS) on these conditions, and their effect on mental health. It also assesses the availability and uptake of professional training for healthcare providers and available treatments for affected women.
Supporters argue
Supporters argue this evaluation is crucial for understanding the unique health challenges faced by servicewomen and veterans during menopause and perimenopause, especially considering service-related exposures and stressors. It will lay the groundwork for evidence-based improvements in care and support.
Critics contend
No specific opposition is typically raised against a provision focused on evaluating research and identifying gaps in women's health, particularly for veterans and servicemembers. Any potential concerns would likely be about resource allocation, which is generally considered a minor cost for an evaluation.
Tradeoffs
The primary tension is balancing the thoroughness of the evaluation with the resources and time available to DoD and VA. There's also a need to ensure the evaluation is truly comprehensive and doesn't miss critical areas, while avoiding duplication of efforts with other federal health agencies.
Section 2(b)
Congressional Report and Strategic Plan for Research
This section requires the Secretary of Defense and the Secretary of Veterans Affairs to submit a report to Congress within 180 days of the bill's enactment. This report must detail the findings from the evaluation conducted under subsection (a), include recommendations for improving professional training resources for healthcare providers regarding mid-life women's health, and present a strategic plan. This strategic plan is intended to address the identified knowledge and research gaps and pinpoint specific topics requiring further research into potential treatments for menopause-related symptoms in servicewomen and veterans.
This subsection mandates that the activities carried out by the Secretary of Defense and the Secretary of Veterans Affairs under this section must supplement, and minimize the duplication of, existing efforts of the Secretary of Health and Human Services to share information regarding the matters described in subsection (a).
Section 2(c)
Why it matters:Standard legislative practice to ensure inter-agency coordination and efficiency, preventing redundant work.
Case for: Proponents argue this ensures efficient use of taxpayer dollars and leverages existing expertise within the federal government, preventing DoD and VA from 'reinventing the wheel' when HHS may already have relevant data or programs.
Case against: Critics might argue that while well-intentioned, such coordination mandates can sometimes lead to bureaucratic delays or dilute the specific focus on military and veteran populations if too much reliance is placed on general population research from HHS.
Estimated impact: Prevents potential waste and promotes inter-agency collaboration, likely leading to more efficient research efforts.
This subsection provides specific definitions for key terms used in the Act, including 'covered provider,' 'menopause,' 'mid-life,' 'perimenopause,' 'PFAS,' and 'postmenopausal.' These definitions clarify the scope and intent of the research and evaluation. For example, 'menopause' is explicitly defined as 'not a disease state, but a normal part of aging for women.' 'Mid-life' is given a broad age range (35-65) and notes its association with chronic disease onset.
Section 2(d)
Why it matters:Standard legislative practice to ensure clarity and avoid ambiguity in legal text.
Case for: Proponents argue precise definitions are essential for consistent implementation and research, ensuring all agencies and researchers are working with the same understanding of the terms. Defining menopause as a normal part of aging, for instance, frames the research appropriately.
Case against: No specific opposition to providing clear definitions.
Estimated impact: Ensures clarity and consistency in the execution of the Act's directives.